CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data

CalciMedica, Inc.

Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.
Cash, equivalents and short-term investments $19.1M as of June 30, 2024; runway into H2 2025.
Phase 2b CARPO trial for Auxora in acute pancreatitis met primary objective with statistically significant dose response.
First patient dosed in Phase 2 KOURAGE trial for severe AKI; topline data expected in 2025.
Company added to Russell Microcap Index effective July 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.